RAPT Therapeutics’ $58-Per-Share GSK Deal Faces Fiduciary Duty Probe
Halper Sadeh LLC is investigating RAPT Therapeutics’ $58-per-share sale to GSK plc for potential breaches of fiduciary duties and restricted competing offers, offering shareholders contingency-fee legal representation. The probe joins inquiries into Allegiant Travel’s merger, Lisata Therapeutics’ $4 cash-plus-CVR sale and Mission Produce’s 80.3% post-merger stake.
1. Investigation Launched
Halper Sadeh LLC has launched an inquiry into RAPT Therapeutics’ sale to GSK plc, probing potential breaches of fiduciary duties and federal securities laws. The firm is examining whether insiders may receive preferential financial benefits and if deal terms limited superior competing bids.
2. Deal Terms
Under the agreement, GSK will acquire RAPT Therapeutics at $58 per share in cash. The investigation scrutinizes provisions that could restrict alternative offers or undervalue the company’s assets and pipeline.
3. Shareholder Remedies
Shareholders are offered no-cost, contingency-fee legal representation to pursue increased deal consideration, additional disclosures or other relief. The firm anticipates seeking enhanced returns or structural adjustments on behalf of affected shareholders.
4. Potential Implications
An adverse finding or legal challenge could delay transaction closing, trigger renegotiation of terms or open the door for rival bids. Any modifications may materially impact valuation and timing for RAPT shareholders.